Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2018

Published : Jan-2019

No. of Pages : 98

order by fax Inquire before Buying request discount

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q3 2018
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q3 2018
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q3 2018
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q3 2018
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2018
2.4.1 AbbVie Raises USD6 Billion in Public Offering of Notes
2.4.2 Pfizer Raises USD4 Billion in Public Offering of Notes
2.4.3 Abbott Labs Raises USD4 Billion in Public Offering of Bonds
2.4.4 Affimed to Enter into Co-Development Agreement with Genentech
2.4.5 Consortium of Investors to Acquire Remaining Shares in China Biologic Products for USD3.9 Billion
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2018
3.1.1 Top M&A Deals in Q3 2018
3.1.3 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q3 2017 - Q3 2018
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2018
3.2.1 Top Initial Public Offerings in Q3 2018
3.2.2 Top Secondary Offerings in Q3 2018
3.2.3 Top PIPE Deals in Q3 2018
3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2017 - Q3 2018
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2018
3.3.1 Top Venture Financing Deals in Q3 2018
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2018
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2018
3.3.5 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2017 - Q3 2018
3.3.6 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q3 2017 - Q3 2018
3.3.7 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2017 - Q3 2018
3.5 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q3 2018
3.5.1 Top Private Equity Deals in Q3 2018
3.5.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2017 - Q3 2018
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2018
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2018
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2017 - Q3 2018
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2018
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q3 2018
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2018
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q3 2018
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 - Q3 2018
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q3 2017 - Q3 2018
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q3 2017 - Q3 2018
4.8 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 - Q3 2018
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2018
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q3 2018
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 - Q3 2018
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2018
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q3 2018
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2018
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2017 - Q3 2018
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q3 2017 - Q3 2018
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2017 - Q3 2018
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q3 2017 - Q3 2018
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q3 2017 - Q3 2018
6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q3 2018
6.1.1 Oncology - Deals of the Quarter
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q3 2018
6.2.1 Central Nervous System - Deals of the Quarter
6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q3 2018
6.3.1 Infectious Disease - Deals of the Quarter
6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q3 2018
6.4.1 Immunology - Deals of the Quarter
6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q3 2018
6.5.1 Metabolic Disorders - Deals of the Quarter
6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q3 2018
6.6.1 Cardiovascular - Deals of the Quarter
6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q3 2018
6.7.1 Gastrointestinal - Deals of the Quarter
6.8 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q3 2018
6.8.1 Dermatology - Deals of the Quarter
6.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q3 2018
6.9.1 Respiratory - Deals of the Quarter
6.10 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q3 2018
6.10.1 Ophthalmology - Deals of the Quarter
7 Deal Summary by Geography
7.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q3 2018
7.1.1 North America - Deals of the Quarter
7.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q3 2018
7.2.1 Europe - Deals of the Quarter
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q3 2018
7.3.1 Asia-Pacific - Deals of the Quarter
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q3 2018
7.4.1 Rest of the World - Deals of the Quarter
8 Pharmaceuticals & Healthcare, Global, Top Advisors
8.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q3 2017 - Q3 2018
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q3 2017 - Q3 2018
9 Further Information
9.1 Methodology
9.2 About GlobalData
9.3 Contact Us
9.4 Disclosure information
9.5 Disclaimer

1.1 List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q3 2017 - Q3 2018
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q3 2018
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2018
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q3 2018
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, , Q3 2017 - Q3 2018
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2017 - Q3 2018
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q3 2018
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q3 2018
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q3 2018
Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2017 - Q3 2018
Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q3 2018
Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q3 2018
Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2017 - Q3 2018
Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2017 - Q3 2018
Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q3 2018
Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$m), Q3 2017 - Q3 2018
Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2018
Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2018
Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2018
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2017 - Q3 2018
Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q3 2018
Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2018
Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2018
Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q3 2017 - Q3 2018
Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2017 - Q3 2018
Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 39: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 40: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 41: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 42: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 43: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 44: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 45: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 46: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 47: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 48: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 49: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 50: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 51: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 52: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 53: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Table 54: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018

1.2 List of Figures
Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$m), Q3 2017 - Q3 2018
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q3 2018
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q3 2018
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$m), Q3 2017 - Q3 2018
Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q3 2017 - Q3 2018
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m), Q3 2017 - Q3 2018
Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q3 2018
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q3 2018
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2017 - Q3 2018
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q3 2017 - Q3 2018
Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2017 - Q3 2018
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2017 - Q3 2018
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q3 2017 - Q3 2018
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 29: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 30: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 31: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 32: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 35: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 36: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 38: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 39: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 40: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 41: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 42: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018
Figure 44: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q3 2017 - Q3 2018

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2018

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027